^
    3d
    Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. (PubMed, J Hematol Oncol)
    Phase 1 studies of docirbrutinib and rocbrutinib demonstrated target engagement across wild-type and resistance-associated BTK mutations with encouraging safety profiles and preliminary efficacy signals in heavily pretreated populations...BTK degraders, including bexobrutideg and BGB-16673, demonstrated rapid and deep responses, activity in high-risk molecular subgroups, and manageable toxicity profiles, with recommended phase 2 doses established. Collectively, these latest updates support continued clinical development of novel agents to address resistance and disease progression in R/R CLL/SLL.
    Journal • IO biomarker
    |
    LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase)
    |
    bexobrutideg (NX-5948) • catadegbrutinib (BGB-16673) • docirbrutinib (AS-1763) • rocbrutinib (LP-168)
    14d
    A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=92, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P1/2 trial
    |
    lacutoclax (LP-108) • rocbrutinib (LP-168)
    1m
    A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P1 trial
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • rocbrutinib (LP-168)
    1m
    ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (clinicaltrials.gov)
    P3, N=306, Recruiting, Newave Pharmaceutical Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Jaypirca (pirtobrutinib) • rocbrutinib (LP-168)
    3ms
    A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (clinicaltrials.gov)
    P1, N=28, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    itraconazole • rifampicin • rocbrutinib (LP-168)
    4ms
    LP-168-US-I01: Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. (clinicaltrials.gov)
    P1, N=60, Recruiting, Newave Pharmaceutical Inc | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    rocbrutinib (LP-168)
    4ms
    A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P3, N=394, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P3 trial
    |
    Imbruvica (ibrutinib) • Brukinsa (zanubrutinib) • Calquence (acalabrutinib) • Inokai (orelabrutinib) • rocbrutinib (LP-168)
    4ms
    A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (clinicaltrials.gov)
    P1, N=28, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P1 trial
    |
    itraconazole • rifampicin • rocbrutinib (LP-168)
    5ms
    LP-168-CN201: A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=62, Active, not recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    rocbrutinib (LP-168)
    5ms
    ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL (clinicaltrials.gov)
    P3, N=306, Not yet recruiting, Newave Pharmaceutical Inc
    New P3 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2)
    |
    TP53 mutation
    |
    Jaypirca (pirtobrutinib) • rocbrutinib (LP-168)
    6ms
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Recruiting, Guangzhou Lupeng Pharmaceutical Company LTD. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)
    9ms
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=150, Not yet recruiting, Guangzhou Lupeng Pharmaceutical Company LTD.
    New P2 trial
    |
    Rituxan (rituximab) • lenalidomide • bendamustine • rocbrutinib (LP-168)